Akers Biosciences Share Discussion Threads

[aim_trader] 24/4/2015 09:38

To view Akers Biosciences’ presentation from last night’s Proactive Investors One2One Investor Forum, click on the following link:

[werewolfie] 23/4/2015 21:44

Why didnt i get the six pack in for that presentation?

[rivaldo] 23/4/2015 07:32

AKR presented again in the USA yesterday - can't see it online at all yet?

[norbus] 23/4/2015 02:16

He used to keep an old goat to make antibodies; the goat died, so maybe he replaced Billy with an Ass

[werewolfie] 22/4/2015 17:53

Did he mention "Kick Ass" or "Blockbuster" products? He likes!

[rivaldo] 22/4/2015 15:44

It seems to me that AKR were operating from a position of great strength re increasing the price of the heparin kit - the amount of the saving is simply so large that this really won't make any difference to the purchasers.

I very much doubt we'll see those additional salesmen's numbers in the Q1 results since they're only recently on stream - I'd say this quarter going into Q3 will see the more dramatic sales increase.

"Well-being" was certainly mentioned, but relatively briefly and I didn't take that many notes!

[rivaldo] 22/4/2015 12:33

Brief notes from last night's presentation - apologies if anything written down/understood incorrectly:

Sales should be up to $7.2m this year, with breakeven during the period, and ending with approx.$10m cash (i.e almost 50% of the m/cap).

AKR can produce $50m of sales from their existing facilities, so there's no need for material capital expenditure.

Heparin test

- the price of AKR's Heparin test is to be INCREASED from May 1st, due to the huge savings for hospitals
- 10 new sales reps are each opening 3 new hospital/customer accounts per month, each selling $30k per annum, which I calculate to be $10.8m revenues per annum once a year's selling is up and running
- there should be one or two further Chinese orders this year

Cholesterol test is perfect for Australia given distances/flying doctors etcf, and has achieved $900,000 of unbudgeted sales

5 products currently on the market, growing soon to 11

Future products include (1) breath test for lung cancer, (2) test for type 1 diabetics, at 73% margins (this is AKR's lowest margin test!), (3) chlamydia test, to be perfected this summer after clinical trials.

AKR's great advantage is that clinical trials only take a few months and cost relatively little.

The diabetes test will be launched in China and USA this year. AKR already have a Chinese facility. I think he said the asthma test is this year too.

There's no competition for the heparin and other breath tests (except the alcohol test in Europe).

[rivaldo] 22/4/2015 09:16

Good to see 5,000 shares bought first thing this morning at 320p.

Hopefully a reaction to last night's very good presentation by Ray Akers at Finncap (organised by Sharesoc), which reinforced my positive opinion about the company.

More later.

[werewolfie] 20/4/2015 17:51

Star Wars is new to some

[rivaldo] 20/4/2015 08:33

Nice coverage in last week's Independent:



"Pioneering drug company boosted by marketing deal

One Alternative Investment Market company hoping to buck the general malaise on the junior market is Akers Biosciences, which will today announce a deal to begin marketing one of its flagship treatments in Britain and eight other European countries.

Akers, which has a dual Aim and Nasdaq listing, has developed a pioneering new test that can rapidly detect whether patients have a potentially fatal allergy to heparin, the blood thinning drug routinely used in hospitals around the world. The test is already in use in the US healthcare systems but Akers will now begin selling it far more widely across Europe, the Middle East and Africa.

The potential for the test is enormous – while millions are prescribed heparin, as many as 5 per cent of them develop an allergy to the product. Patients undergoing serious heart surgery or major orthopaedic procedures are regarded as particularly vulnerable to such problems."

[mcmather] 14/4/2015 14:05

$5.25 nasdaq equates to around £3.57 aim.

[mcmather] 14/4/2015 14:03

Admitted limited knowledge of all things TA but, on Nasdaq, the prospects of the company (AKER) do appear bullish at the moment:

India, April 14 -- Medical device company Akers Biosciences Inc. (AKER) touched a 52-week high on Monday after announcing that it has added six new distributors to market its rapid tests for heparin-induced thrombocytopenia in nine additional countries within Europe, the Middle East and Africa.

In after-hours, the stock was up another 4% at $5.20.


AKER closed up 8.7 percent on Monday, April 13, 2015, on 7.56 times normal volume. The bulls were able to push the stock to a new 52-week high.


Interesting chart here from the 4-traders site:

[werewolfie] 13/4/2015 17:59

AIM Trader - no thanks I have a sock drawer that needs tidying. Wasting my precious free time on Dr Walts hot air

[aim_trader] 13/4/2015 14:36

Dr. Akers to present on 23rd April at the Chesterfield Mayfair. Click here to register;

[norbus] 13/4/2015 10:51

mcm

Amount of time you spend on AKR,entitles you to be on the payroll; The whole RNS imo is framed to suggest traction and critical mass in market penetration smacks of a made up job ; where indeed are the sales, now focused on one product; Notice there is always a blockbuster round the corner; Have you thought about coming into CAP and ITM, They are both looking solid and I feel very comfortable there
my reasons are spelled out on a post I made on IEH

[mcmather] 13/4/2015 10:28

It is something but agree norbus re notable no concrete orders but especially as sales of the device in the US have effectively flat-lined since 2008 despite the introduction of the PIFA Pluss device, whilst sales outside of the US is not entirely new; see post 2820.


Pathway Diagnostics Ltd - website under development;

Christopher Bellamy is the person behind Pathway Diagnostics Ltd;

It may be nothing but he is also behind a company which changed its name to VIVO Medical Ltd on 20 Oct 2010 ; Akers of course having their own device called VIVO -





or a bit in English

website under construction

No website found for Masterlab SARL;

[rivaldo] 13/4/2015 09:06

Buying coming in at 315p now.

[norbus] 13/4/2015 07:47

Someone is connecting the dots; initial stocking orders would have helped credibility

a bit more action , and Dr A will get into performance bonuses :-) Roll on 21st April

[norbus] 09/4/2015 11:49

mcm

Best take some shortbread and haggis to the good doctor on 21st April;

[rivaldo] 07/4/2015 07:34

AKR still performing well and at around 310p in the USA.

The CEO is presenting in London on 21st April...hopefully he'll have news flow to promote:

[mcmather] 04/4/2015 12:53

WW, it wasn't; the agreement enabled government agencies to purchase, effectively, all of Akers' commercialised products at that time:

"The Contract, number GS-07F-0140W, applies to a variety of the Company's single-use assays including the PIFA Heparin/PF4 Rapid Assay..."

The "BreathScan keychain unit which is currently in use by the US Military as part of their Personally Owned Vehicle (POV) Safety Program" alluded to above, was actually subject to significant ($multi-million) sales prior to Dec 2009 and, if memory serves me right, was the main reason why Akers purchased the device / technology / the company who was producing the same around 2005?

As stated, might be wrong; in a rush as off out to the match in a bit; got utd to win without conceding but in a double with west brom to do likewise @ 5/1.